Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
Agency: | |
---|---|
Level of Government: | Federal |
Category: |
|
Opps ID: | NBD00159688547791993 |
Posted Date: | Feb 29, 2024 |
Due Date: | Mar 21, 2024 |
Source: | https://sam.gov/opp/478230f89c... |
APEX Accelerators are an official government contracting resource for small businesses. Find your local APEX Accelerator (opens in new window) for free government expertise related to contract opportunities.
APEX Accelerators are funded in part through a cooperative agreement with the Department of Defense.
The APEX Accelerators program was formerly known as the Procurement Technical Assistance Program (opens in new window) (PTAP).
- Contract Opportunity Type: Solicitation (Original)
- All Dates/Times are: (UTC-06:00) CENTRAL STANDARD TIME, CHICAGO, USA
- Original Published Date: Feb 29, 2024 02:03 pm CST
- Original Date Offers Due: Mar 21, 2024 12:00 pm CDT
- Inactive Policy: Manual
- Original Inactive Date: Sep 21, 2024
-
Initiative:
- None
- Original Set Aside:
- Product Service Code: 6505 - DRUGS AND BIOLOGICALS
-
NAICS Code:
- 325412 - Pharmaceutical Preparation Manufacturing
-
Place of Performance:
San Antonio , TX 78230USA
The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.
P&T COMMITTEE MEETING: May 2024: The following newly approved drugs will be reviewed:
a. Alvaiz - Hematological Agents - Subclass: Platelets
b. Bosulif - Oncological Agents - Subclass: NA
c. Filsuvez - Skin Preps - Subclass: Irritants Counter-Irritants
d. Rivfloza - Oncological Agents - Subclass: NA
e. Xolair Auto-Injector - Atopy - Subclass: NA
The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-24-Q-9204.
Pre-quotation teleconference is on March 6, 2024, details are stated in Part 2.5. Pre-quotation teleconference, contact RFQ Point of Contact (POC) for agenda and dial-in information. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC (stated in Part 2.3), no later than the date stated in Part 2.4.
- MANAGED CARE CONTRACT DIRECTORATE 16401 E. CENTRETECH PKWY, ATTN: AEA
- AURORA , CO 80011
- USA
- Tracy Banks
- tracy.e.banks2.civ@health.mil
- Keith Marasigan
- keith.b.marasigan2.ctr@health.mil
- Feb 29, 2024 02:03 pm CSTSolicitation (Original)
TRY FOR FREE
Not a USAOPPS Member Yet?
Get unlimited access to thousands of active local, state and federal government bids and awards in All 50 States.